Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17573048 | 0.88 | OPRK1 (0.53) | GPR119OPRK1KCNH2KDM2B | |
| SCHEMBL12094619 | 0.86 | GPR119 (0.51) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12094676 | 0.86 | GPR119 (0.51) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12667813 | 0.86 | GPR119 (0.51) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12094702 | 0.86 | GPR119 (0.51) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12345354 | 0.85 | GPR119 (0.50) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12094630 | 0.84 | GPR119 (0.49) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL16421279 | 0.83 | GPR119 (0.48) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12094621 | 0.83 | GPR119 (0.48) | GPR119OPRK1KCNH2CHRM2CHRM1 | |
| SCHEMBL12094651 | 0.83 | GPR119 (0.48) | GPR119OPRK1KCNH2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | GPR119 3993/4885OPRK1 2595/4885KCNH2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.